IMA
ImageneBio, Inc.
Healthcare — Biotechnology
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
None
1 analysts
$4.59
+$0.01 (+0.22%)
Target:
$24.00
(422.9%)
Price History
52-Week Range
Sign in to add IMA to a watchlist or set price alerts.
Fundamentals
| Market Cap | $65.08M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.45 |
| EPS (TTM) | $-4.78 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -86.16% |
| Debt/Equity | 1.96 |
| Recommendation | None |
| Analyst Target | $24.00 |
| Analysts | 1 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 58.4 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $18.00 |
| 52-Week Low | $3.94 |
| 50-Day Avg | $5.74 |
| 200-Day Avg | $6.62 |
| Avg Volume | 351.7K |
| Volume | 9.9K |
Performance Analysis
BULLISHIMA shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($3.94), which could present a value opportunity.
+
RSI at 58.4 shows positive momentum.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none" from 1 analysts.
+
Average analyst target of $24.00 implies 422.9% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:15 UTC
Back to Screener Export Report